Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase

21 Jan 2016

Abstract excerpt

CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth. CUDC-907 is currently under evaluation in phase I clinical trials in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Histone Deacetylase Inhibitors Research
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26796063
DOI: 10.1021/acs.molpharmaceut.5b00687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-KinasePMID 26796063Read ↗

Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2Semantic proximity Read ↗

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Semantic proximity Read ↗

Dynamic vs Static ABCG2 Inhibitors to Sensitize Drug Resistant Cancer CellsSemantic proximity Read ↗

Mechanisms of tumor cell resistance to the current targeted-therapy agents.Semantic proximity Read ↗

Molecular pharmacology of ABCG2 and its role in chemoresistance.Semantic proximity Read ↗

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cellsSemantic proximity Read ↗

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to ChemotherapySemantic proximity Read ↗

Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) InhibitorSemantic proximity Read ↗

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.Semantic proximity Read ↗

Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.Semantic proximity Read ↗

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistanceSemantic proximity Read ↗

ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.